Efficacy and safety of tisotumab vedotin versus investigator's choice of chemotherapy in second-line or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT-cx12/GOG-3057): A global, randomized, open-label, phase III study | Publicación